Treatment options for radiation-induced xerostomia in patients with head and neck cancer: a systematic review and meta-analysis.
Radiation-induced xerostomia is a frequent and debilitating complication in patients undergoing radiotherapy for head and neck cancer.
- p-value p < 0.00001
- p-value p < 0.0001
- 95% CI 0.09 to 0.17
APA
Shrateh ON, Habib A, et al. (2026). Treatment options for radiation-induced xerostomia in patients with head and neck cancer: a systematic review and meta-analysis.. The British journal of oral & maxillofacial surgery, 64(1), 24-32. https://doi.org/10.1016/j.bjoms.2025.10.003
MLA
Shrateh ON, et al.. "Treatment options for radiation-induced xerostomia in patients with head and neck cancer: a systematic review and meta-analysis.." The British journal of oral & maxillofacial surgery, vol. 64, no. 1, 2026, pp. 24-32.
PMID
41253620
Abstract
Radiation-induced xerostomia is a frequent and debilitating complication in patients undergoing radiotherapy for head and neck cancer. This study aimed to compare the effectiveness of available treatment modalities in preventing or managing radiation-induced xerostomia and associated complications in head and neck cancer patients. A detailed search of PubMed and Google Scholar was conducted. Only randomised controlled trials (RCTs) involving radiotherapy-treated head and neck cancer patients were included. The interventions that were analysed encompassed pharmacological agents (for example, pilocarpine, and amifostine), antioxidants, herbal formulations, acupuncture, low-level laser therapy (LLLT), and regenerative approaches. Primary outcomes included severity of xerostomia, rates of salivary flow, mucositis, oral pain, dysphagia, and fatigue. Thirty-one randomised clinical trials met the inclusion criteria. Pooled analysis showed no significant reduction in severity of xerostomia at weeks 3, 4, or 6, or 6 months. Stimulated salivary flow did not significantly improve (mean difference (MD): 0.22; p = 0.15), while unstimulated salivary flow showed a significant benefit (MD: 0.13; 95% CI: 0.09 to 0.17; p < 0.00001). A significant reduction in the severity of oral pain was also noted (MD: -2.25; p < 0.0001). No significant differences were found for the incidence or duration of mucositis, dysphagia, or fatigue. Considerable heterogeneity was observed across the studies and no single intervention demonstrated consistent efficacy in managing radiation-induced xerostomia. Some therapies have shown promise in improving unstimulated salivary flow and reducing oral pain; however, the overall evidence remains inconclusive. To address this persistent clinical challenge, future trials should adopt standardised outcome measures, assess combination therapies, and investigate novel regenerative strategies.
MeSH Terms
Humans; Xerostomia; Head and Neck Neoplasms; Radiation Injuries; Randomized Controlled Trials as Topic; Radiotherapy